World's Best Scientists 2026 revealed!
Alfredo Falcone

Alfredo Falcone

D-Index & Metrics

Medicine

D-Index
95
Citations
45015
World Ranking
9897
National Ranking
349

Alfredo Falcone publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Alfredo Falcone sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,122 publications — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Alfredo Falcone D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Alfredo Falcone sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Alfredo Falcone is affiliated with the University of Pisa in Italy, specializing in medical research with a focus on oncology. Their work encompasses a broad range of studies on cancer treatment and related fields.

Falcone's research primarily focuses on the following topics:

  • Colorectal Cancer Treatments and Studies
  • Genetic factors in colorectal cancer
  • Cancer Genomics and Diagnostics
  • Cancer Treatment and Pharmacology
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Gastric Cancer Management and Outcomes
  • Cancer Immunotherapy and Biomarkers

Their contributions span across several subfields of study within medicine, including:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Pathology and Forensic Medicine
  • Hepatology

Alfredo Falcone has co-authored extensively with several researchers, indicating collaborative work within the oncology community. Frequent coauthors include:

  • Chiara Cremolini
  • Daniele Rossini
  • Heinz-Josef Lenz
  • Carlotta Antoniotti
  • Gianluca Masi

The primary venues for Falcone's research publications are journals focused on clinical oncology and cancer research, which include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • Cancers
  • ESMO Open

Some of the recent publications authored or coauthored by Alfredo Falcone are:

  • Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial, 2023, The Lancet
  • Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial, 2020, The Lancet Oncology
  • Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer, 2020, Journal of Clinical Oncology
  • Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma, 2024, Annals of Oncology
  • Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment, 2022, ESMO Open

Alfredo Falcone's published research outputs contribute to the understanding and treatment of advanced and metastatic cancers, including colorectal cancer and hepatocellular carcinoma, with a clinical focus spanning immunotherapies, combination chemotherapies, and lung disease related to cancer treatments.

Best Publications

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    Axel Grothey;Eric Van Cutsem;Alberto Sobrero;Salvatore Siena

  • Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest

    Alfredo Falcone;Sergio Ricci;Isa Brunetti;Elisabetta Pfanner

  • Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

    Robert J Mayer;Eric Van Cutsem;Alfredo Falcone;Takayuki Yoshino

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

    Chiara Cremolini;Fotios Loupakis;Carlotta Antoniotti;Cristiana Lupi

  • Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

    Fotios Loupakis;Chiara Cremolini;Gianluca Masi;Sara Lonardi

  • Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

    Giulia Siravegna;Benedetta Mussolin;Michela Buscarino;Giorgio Corti

  • KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

    F Loupakis;A Ruzzo;C Cremolini;B Vincenzi

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

    Jan Franko;Qian Shi;Jeffrey P Meyers;Timothy S Maughan

  • MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity

    Elisa Giovannetti;Niccola Funel;Godefridus J. Peters;Marco Del Chiaro

  • Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

    Cathy Eng;Tae Won Kim;Johanna Bendell;Guillem Argilés

  • PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

    Fotios Loupakis;Luca Pollina;Irene Stasi;Annamaria Ruzzo

  • Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer

    Fotios Loupakis;Dongyun Yang;Linda Yau;Shibao Feng

  • Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

    Josep Tabernero;Heinz Josef Lenz;Salvatore Siena;Alberto Sobrero

  • Quantitative evidence for early metastatic seeding in colorectal cancer.

    Zheng Hu;Jie Ding;Zhicheng Ma;Ruping Sun

  • Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy

    Annamaria Ruzzo;Francesco Graziano;Fotios Loupakis;Eliana Rulli

  • Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.

    Chiara Cremolini;Daniele Rossini;Emanuela Dell’Aquila;Sara Lonardi

  • KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

    A. Ruzzo;F. Loupakis;E. Canestrari;Chiara Cremolini

Frequent Co-Authors

Fotios Loupakis
Fotios Loupakis Istituto Oncologico Veneto
Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Romano Danesi
Romano Danesi University of Pisa
Daniele Santini
Daniele Santini Università Campus Bio-Medico
Heinz-Josef Lenz
Heinz-Josef Lenz University of Southern California
Gabriella Fontanini
Gabriella Fontanini University of Pisa
Stefano Cascinu
Stefano Cascinu Vita-Salute San Raffaele University
Giuseppe Tonini
Giuseppe Tonini Università Campus Bio-Medico
Bruno Vincenzi
Bruno Vincenzi Università Campus Bio-Medico
Pierfranco Conte
Pierfranco Conte University of Padua

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative career options and degrees in healthcare can open many exciting doors beyond traditional medical school. One in-demand field is medical billing and coding schools online, which offer flexible programs for those interested in the administrative side of healthcare, with financial aid often available.

For those drawn to patient care, nursing is a rewarding path with several accessible options. If you want a faster route and fewer testing barriers, consider a nursing school that don't require teas—these programs waive common entrance exams, allowing you to focus on your studies.

If healthcare leadership interests you, pursuing healthcare administration degrees can lead to roles in hospital or clinic management, with many accelerated online options catering to busy professionals.

Current RNs looking to advance their careers may benefit from rn to np bridge programs. These pathways help nurses earn advanced practice credentials more efficiently, expanding their scope of practice and earning potential.

Best Scientists Citing Alfredo Falcone

Trending Scientists

Recently Published Articles